Xencor shares rose to a new record on Thursday after the biopharmaceutical company said it has begun dosing patients in the latest phase of a trial of subcutaneously administered XmAb7195, a potential treatment for allergic disease. XNCR was up nearly 4% at $24.21 recently, having earlier traded as high as $24.55. The 52-week low is at $9.89.
Complete data results from an earlier phase of the trial showed that XmAb7195 was generally well tolerated, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects.
The company said it expects to report interim data from the trial in 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.